Australian Anti-Fungal Drugs Market Report with Executive Summary, Size, Analysis and Forecast to 2023-2028

Report Overview

The Australian Anti-Fungal Drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Fungal infections represent the invasion of tissues by one or more species of fungi. They range from superficial, localized skin conditions to deeper tissue infections to serious lung, blood (septicemia), or systemic diseases. Some fungi are opportunistic while others are pathogenic, causing disease whether the immune system is healthy or not. Histoplasmosis, caused by Histoplasma capsulatum is a rare disease in Australia and most cases have been associated with visiting bat caves. It typically affects the lungs. Blastomycosis, caused by Blastomyces dermatitidis and Coccidiomycosis, caused primarily by Coccidioides immitis cannot be acquired in Australia but may occur in people who have traveled to regions of North America where these fungi are found. Fungal infections include both systemic and superficial infections such as infections of the skin, eye, mouth, and vagina. Antifungal products with fungicidal activity are mostly used to treat a wide array of diseases, such as athlete's foot, ringworm, and fungal meningitis, caused by fungal agents.

Market Drivers

The major factors augmenting the growth of the anti-fungal drugs market include increasing awareness about the myriad fungal infections, increasing the number of antifungal drugs available over the counter (OTC), and rising consumption of anti-fungal drugs in developing regions for a variety of medical conditions.

With the rising popularity of over-the-counter (OTC) drugs, many patients prefer OTC drugs over obtaining a prescription from a healthcare professional. Numerous common and harmless fungal infections are left untreated by patients, owing to medical costs and logistical constraints. These have directly contributed to the rise in the usage of OTC drugs, as these infections can be treated by OTC drugs, owing to their ease of availability. The increased usage of OTC drugs has further contributed to the rise in anti-fungal drug sales over the years. Besides, the anti-fungal drugs market is expected to grow at a steady pace owing to the rising research and development activities.

Epidemiology

Candidemia is a common invasive fungal infection with a high mortality rate. In Western Australia, 2005-2014. There were 167 episodes of candidemia due to 173 isolates of Candida. Candida albicans (40.5%), Candida glabrata complex (30.6%), Candida parapsilosis complex (14.4%) were the most common species causing candidemia across the study. Of the tested isolates, 17.7% (11/62) were non-susceptible to fluconazole and 13.6% (9/66) non-susceptible to caspofungin. 22.8% (8/35) C. glabrata complex were fluconazole resistant and 17.1% (6/35) were non-susceptible to caspofungin.

Get Exclusive Free Sample Report @ https://www.prudentmarkets.com/sample-request/140023/

Major Players

The market is fragmented, owing to the presence of many small and big players. Some of the market players are Mayne Pharma, Abbott Laboratories, Bayer AG, Astellas Pharma Inc., Glenmark, GlaxoSmithKline PLC, Kramer Laboratories, Merck & Co. Inc., Novartis AG, Pfizer Inc., and SCYNEXIS Inc.

On 2 May 2018, Mayne Pharma has received regulatory approval for SUBA-itraconazole capsules in Australia, Argentina, Belgium, Germany, Mexico, Italy, and Spain, and is seeking approval in other countries around the world.

The report delivers the challenges in front of the Australian Anti-Fungal Drugs Market 2023 that allows a better understanding of the market providing a helpful comprehensive evaluation and clear-cut dynamics associated with this market. The analyst has studied the current market scenario while concentrating on the new business objectives with the lucrative opportunities that are available. This report includes changes in customer requirements, customer preferences, and the vendor landscape in the industry with key factors that are expected to influence the overall dynamics of the Australian Anti-Fungal Drugss Market including the current trends, growth opportunities, restraints, and market drivers.

To Know More About COVID-19 Impact On Australian Anti-Fungal Drugs Market @ https://www.prudentmarkets.com/sample-request/140023/

Market Segmentation

By Drug Type:

The Azoles Segment is Expected to be among the major contributors to the market. Anti-fungal drug research is gaining momentum, owing to the development of new antifungal drugs using the azole group. Azoles are synthetic and semi-synthetic compounds, widely used for superficial and invasive fungal infections. The drugs are used to treat thrush, yeast infection, candidiasis, aspergillosis, tinea versicolor, athlete's foot, jock itch, ringworm, nail fungus, fungal infections, systemic mycosis, and seborrheic dermatitis. The azole anti-fungal group includes two classes, namely the triazoles (fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole) and the imidazole.

Triazoles have a broad range of applications in the treatment of superficial and systemic fungal infections. The azoles are currently the most widely used and studied class of antifungal agents. The drugs are available in different formulations (oral tablet, oral capsule, cream, dandruff shampoo, sterile IV solution, lotion, vaginal cream, and tablet). Sales of both the established agents and newly launched anti-fungal agents are significant.

By Indication:

The indication segment includes Dermatophytosis, Aspergillosis, Candidiasis, and others. The Candidiasis segment is anticipated to grow over the forecast period. The growing incidence of thrush or oropharyngeal candidiasis that develops in the mouth or throat is anticipated to drive the antifungal drugs market over the forecast period.

By Dosage:

The dosage form segment is categorized as drugs, ointment, powder, and others. The ointment segment emerged as the leader in the antifungal drugs market. Owing to the use of topical antifungal in the treatment of skin-related fungal infections is projected to propel the market growth over the forecast period.

Major Players

The market is fragmented, owing to the presence of many small and big players. Some of the market players are Mayne Pharma, Abbott Laboratories, Bayer AG, Astellas Pharma Inc., Glenmark, GlaxoSmithKline PLC, Kramer Laboratories, Merck & Co. Inc., Novartis AG, Pfizer Inc., and SCYNEXIS Inc.

On 2 May 2018, Mayne Pharma has received regulatory approval for SUBA-itraconazole capsules in Australia, Argentina, Belgium, Germany, Mexico, Italy, and Spain, and is seeking approval in other countries around the world.

The Australian Anti-Fungal Drugs Market report is an easy-to-understand document giving section-wise details about the global market. Starting with the brief outline of the overall market, it will put forth the all-inclusive evaluated market statistics and different parameters for the forecast period. The report covers numerous aspects of the Australian Anti-Fungal Drugs market divided into product kind, application, and end-use, offering the report to assist the customers in improving their ability to make precise decisions related to the business under the Australian Anti-Fungal Drugs Market.

International Market Players will use the correct market facts and figures and applied math studies provided within the report back to perceive this and future growth of the worldwide Electrophoretic Australian Anti-Fungal Drugs market. Each section of the research study is specially prepared to explore key aspects of the global Australian Anti-Fungal Drugs Market. Buyers of the report will have access to accurate PESTLE, SWOT, and other types of analysis on the global Australian Anti-Fungal Drugs market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries.

This post-pandemic business planning research will aid clients to:
• Adjust their strategic planning to move ahead once business stability kicks in.
• Build resilience by making effective resource and investment choices for individual business units, products, and service lines.
• Conceptualize scenario-based planning to mitigate future crisis situations.

Instant Buy This Report and Get Up To 40% Discount [Use Corporate Email ID]: https://www.prudentmarkets.com/discount-request/140023/

Get full copy of 225+ pages research report (Inclusion of updated research on COVID-19) on United States Region at $1500 and, Europe region at $2000. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Our qualified team of researchers, analysts, and consultants use in-depth qualitative research, quantitative research, and the latest recognized research techniques to offer an unrivaled level of detail and value to your research activities. Our market and competitive intelligence can be utilized by teams across multiple departments, including sales and business development, marketing, to:

• Access the latest information on potential competitors and customers through a comprehensive database
• Analyse the business strategies and collaborations of multiple companies within a specific market
• Identify new markets and regions for future expansion
• Compare financial trends between competitor companies
• Get to know about mergers and acquisitions
• Explore the strengths and weaknesses of companies cross-industry
• Improve your business modeling

Strategic Points Covered in Table of Content of Global Australian Anti-Fungal Drugs Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Australian Anti-Fungal Drugs market
Chapter 2: Exclusive Summary - the basic information of the Australian Anti-Fungal Drugs Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Australian Anti-Fungal Drugs
Chapter 4: Presenting the Australian Anti-Fungal Drugs Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Australian Anti-Fungal Drugs market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

(If you have any special requirements, please let us know and we will offer you the report as you want.)

Inquire Before Purchasing The Complete Report To Grow Your Business: https://www.prudentmarkets.com/enquiry-request/140023/

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.